Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) p...

Full description

Bibliographic Details
Main Authors: Joschka Bauer, Sven Mathias, Sebastian Kube, Kerstin Otte, Patrick Garidel, Martin Gamer, Michaela Blech, Simon Fischer, Anne R Karow-Zwick
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:mAbs
Subjects:
In silico
bioinformatic
antibody engineering
biotherapeutic development
CMC properties
pharmaceutical industry
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2020.1787121

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2020.1787121

Similar Items